Accelerating the Development of New Products and Businesses
First written in FY2016. 19 of 35 entries say "Restated". Latest entry: FY2026.
25 other companies' latest entry also says "Advanced".
- FY2026AdvancedAnnual report
「During the fiscal year, the Group invested ¥8,075 million in R&D.」
R&D expenditure increased from ¥7,928 million in the previous fiscal year to ¥8,075 million. The Group expanded its R&D structure and external collaboration by establishing the Health Science Research Institute and Materials Science Research Institute, maintaining the collaborative research laboratory with AIST, and soliciting commissioned industry-academia research proposals in the electronics field. - 2026-05-28AdvancedGeneral Meetings of Shareholders
「To accelerate the creation of new technologies and new businesses, we established the Health Science Research Institute, which conducts research in the fields of life and healthcare, and the Material Science Research Institute, which conducts research in the fields of the environment and energy, and electronics and information.」
The disclosure describes concrete progress in the research and development structure through the establishment of research institutes organised by field. - FY2026-H1AdvancedAnnual report
「This fiscal year, we implemented the Open Innovation Program 2025 for Commissioned Industry-Academia Research, soliciting proposals for the development of next-generation materials and technologies in the growing electronics field, contributing to the realization of a sustainable society and the future chemical industry while accelerating the development of new products and technologies. The Group’s total R&D expenditure for the six-month interim consolidated accounting period was ¥4,013 million.」
The Group implemented an open innovation program soliciting proposals focused on next-generation materials and technologies in the electronics field, and recognized R&D expenditure of ¥4,013 million. - FY2025AdvancedAnnual report
「During the fiscal year, the Group invested ¥7,928 million in R&D.」
R&D expenditure increased from ¥7,253 million in the previous fiscal year to ¥7,928 million. The Group established a collaborative research laboratory with the AIST Group and is also pursuing the development of new materials and technologies, including environmentally friendly functional chemicals. - FY2025-H1AdvancedAnnual report
「Beginning this fiscal year, we established the NOF-AIST Smart Green Chemicals Collaborative Research Laboratory at the National Institute of Advanced Industrial Science and Technology (AIST), contributing to the realization of a sustainable society and the future chemical industry while accelerating the development of new products and technologies. The Group’s total R&D expenditure for the six-month interim consolidated accounting period was ¥3,737 million.」
Beginning this fiscal year, the Group established a collaborative research laboratory with AIST, adding a concrete framework for promoting the development of new products and technologies. R&D expenditure for the first half was ¥3,737 million. - FY2024AdvancedAnnual report
「During the fiscal year, the Group invested ¥7,253 million in R&D.」
R&D expenditure increased to ¥7,253 million, while the Group pursued the development and market launch of specific products including plant-based materials, materials for non-fluorinated water and oil repellents, biodegradable lubricants, electronic materials, and materials for medical and medical equipment applications. - FY2024-Q2AdvancedAnnual report
「This fiscal year, we are also pursuing business co-creation through open innovation in the medical and medical equipment fields, following last year’s initiatives in the electronics and health food fields, thereby accelerating the development of new products and technologies. The Group’s total R&D expenditure for the six-month period ended 30 September was ¥3,553 million.」
The scope of business co-creation through open innovation was expanded to the medical and medical equipment fields. R&D expenditure for the first half was ¥3,553 million, with no material changes in the status of R&D activities. - FY2024-Q1RestatedAnnual report
「The Group’s total R&D expenditure for the three-month period ended 30 June was ¥1,795 million. There were no material changes in the status of the Group’s R&D activities during the three-month period ended 30 June.」
The Group disclosed R&D expenditure of ¥1,795 million while continuing to develop new products and technologies, and stated that there were no material changes in the status of its R&D activities. - FY2023-Q3RestatedAnnual report
「The Group’s total R&D expenditure for the nine-month period ended 31 December was ¥4,713 million. There were no material changes in the status of the Group’s R&D activities during the nine-month period ended 31 December.」
R&D expenditure was ¥4,713 million, with no material changes in the status of R&D activities. - FY2023-Q2RestatedAnnual report
「The Group’s total R&D expenditure for the six-month period ended 30 September was ¥3,120 million. There were no material changes in the status of the Group’s R&D activities during the six-month period ended 30 September.」
R&D expenditure was ¥3,120 million, with no material changes in the status of R&D activities. - FY2023-Q1RestatedAnnual report
「The Group’s total R&D expenditure for the three-month period ended 30 June was ¥1,618 million. There were no material changes in the status of the Group’s R&D activities during the three-month period ended 30 June.」
R&D expenditure for the first quarter was ¥1,618 million, with no material changes in the status of R&D activities. - FY2022AdvancedAnnual report
「In addition to conducting research into next-generation materials and technologies at the Advanced Technology Research Institute, we are promoting open innovation through industry-government-academia collaboration in advanced medical care and regenerative medicine in the life science and healthcare fields, using the newly established New Business Development Office and Nano Medical Innovation Center as research hubs. In the electronics and information, and environment and energy fields, we are soliciting commissioned industry-academia research proposals for biochemicals and thermal-control materials, while introducing new technologies and developing next-generation product lines.」
R&D initiatives were made concrete through the New Business Development Office, Nano Medical Innovation Center, open innovation through industry-academia collaboration, and commissioned industry-academia research proposals. R&D expenditure was ¥6,108 million. - FY2022-Q3RestatedAnnual report
「The Group’s total R&D expenditure for the nine-month period ended 31 December was ¥4,644 million. There were no material changes in the status of the Group’s R&D activities during the nine-month period ended 31 December.」
R&D expenditure of ¥4,644 million was recognized, with no material changes in the status of R&D activities. - FY2022-Q2AdvancedAnnual report
「Regarding the acceleration of new product and new technology development, we are promoting active participation in open innovation through industry-government-academia collaboration and working to establish a company-wide R&D structure to improve R&D efficiency through the introduction of MI (materials informatics) using data science. The Group’s total R&D expenditure for the six-month period ended 30 September was ¥3,102 million.」
The Group is making concrete progress on participating in open innovation, introducing MI, and establishing a company-wide R&D structure. R&D expenditure was ¥3,102 million. - FY2022-Q1RestatedAnnual report
「The Group’s total R&D expenditure for the three-month period ended 30 June was ¥1,627 million. There were no material changes in the status of the Group’s R&D activities during the three-month period ended 30 June.」
R&D expenditure for the first quarter was ¥1,627 million, with no material changes in the status of R&D activities. - FY2021AdvancedAnnual report
「To accelerate the development of new products and technologies, the New Business Development Office established within the Research Division last year is pursuing the commercialization of advanced pharmaceutical and medical-related materials, including regenerative medicine materials, while working to expand the Group’s new business areas.」
The Group has progressed to the stage of pursuing the commercialization of advanced pharmaceutical and medical-related materials, including regenerative medicine materials, through the New Business Development Office. - FY2021-Q3RestatedAnnual report
「The Group’s total R&D expenditure for the nine-month period ended 31 December was ¥4,243 million. There were no material changes in the status of the Group’s R&D activities during the nine-month period ended 31 December.」
R&D expenditure of ¥4,243 million was recognized, with no material changes in the status of R&D activities. - FY2021-Q2RestatedAnnual report
「To accelerate the development of new products and technologies, we are expanding research themes and working to launch new products at an early stage, while strengthening industry-government-academia collaboration in Japan and overseas and introducing new technologies. To improve productivity, we are promoting investments in efficiency.」
The Group continued to expand research themes, pursue early product launches, strengthen industry-government-academia collaboration, and introduce new technologies. R&D expenditure was ¥2,842 million, with no material changes in the status of R&D activities. - FY2021-Q1RestatedAnnual report
「The Group’s total R&D expenditure for the three-month period ended 30 June was ¥1,448 million. There were no material changes in the status of the Group’s R&D activities during the three-month period ended 30 June.」
R&D expenditure for the first quarter was ¥1,448 million, with no material changes in the status of R&D activities. - FY2020AdvancedAnnual report
「We will establish a New Business Development Office within the Research Division to pursue the creation of new businesses, while strengthening collaboration inside and outside the Group, including by expanding research themes through joint research in Japan and overseas.」
Specific R&D initiatives expanded to include establishing a New Business Development Office, expanding research themes through joint research, and introducing materials informatics. R&D expenditure was ¥6,148 million. - FY2020-Q3RestatedAnnual report
「The Group’s total R&D expenditure for the nine-month period ended 31 December was ¥4,656 million. There were no material changes in the status of the Group’s R&D activities during the nine-month period ended 31 December.」
R&D expenditure was ¥4,656 million, with no material changes in the status of R&D activities. - FY2020-Q2RestatedAnnual report
「R&D expenditures for the Group as a whole during the second quarter of the current consolidated cumulative period were ¥3,104 million. There were no material changes in the status of the Group’s R&D activities during the second quarter of the current consolidated cumulative period.」
The company stated that R&D expenditures for the first half were ¥3,104 million and that there had been no material changes in the status of its R&D activities. - FY2020-Q1RestatedAnnual report
「R&D expenditures for the Group as a whole during the first quarter of the current consolidated cumulative period were ¥1,579 million. There were no material changes in the status of the Group’s R&D activities during the first quarter of the current consolidated cumulative period.」
The company stated that R&D expenses were ¥1,579 million and that there had been no material changes in the status of its R&D activities. - FY2019AdvancedAnnual report
「For the creation of new products and markets, the company strengthened industry-academia-government collaboration in Japan and overseas, introduced new technologies, expanded its research themes, and worked to accelerate new product launches.」
In addition to strengthening industry-academia-government collaboration, introducing new technologies, and expanding research themes, the company began full-scale user work on water-based zinc-flake treatment agents in its specialty anti-corrosion treatment agent business. R&D expenses were ¥6,406 million. - FY2019-Q3RestatedAnnual report
「R&D expenditures for the Group as a whole during the third quarter of the current consolidated cumulative period were ¥4,884 million. There were no material changes in the status of the Group’s R&D activities during the third quarter of the current consolidated cumulative period.」
The company stated that R&D expenditures were ¥4,884 million and that there had been no material changes in the status of its activities. - FY2019-Q2AdvancedAnnual report
「For the creation of new products and markets, the company strengthened industry-academia-government collaboration in Japan and overseas, introduced new technologies, expanded its research themes, and worked to accelerate new product launches.」
In addition to strengthening industry-academia-government collaboration, the company introduced new technologies, expanded its research themes, and worked to accelerate new product launches. R&D expenditures during the second quarter of the current consolidated cumulative period were ¥3,311 million. - FY2019-Q1RestatedAnnual report
「R&D expenditures for the Group as a whole during the first quarter of the current consolidated cumulative period were ¥1,691 million. There were no material changes in the status of the Group’s R&D activities during the first quarter of the current consolidated cumulative period.」
The company recorded R&D expenses of ¥1,691 million and stated that there had been no material changes in the status of its R&D activities. - FY2018-Q3RestatedAnnual report
「R&D expenditures for the Group as a whole during the third quarter of the current consolidated cumulative period were ¥4,906 million. There were no material changes in the status of the Group’s R&D activities during the third quarter of the current consolidated cumulative period.」
The company stated that R&D expenses were ¥4,906 million and that there had been no material changes in the status of its R&D activities. - FY2018-Q2RestatedAnnual report
「For the creation of new products and markets, the company worked to expand its research themes and accelerate R&D by strengthening industry-academia-government collaboration in Japan and overseas.」
The company reaffirmed the strengthening of industry-academia-government collaboration, the expansion of research themes, and the acceleration of R&D. It stated that R&D expenditures were ¥3,265 million and that there had been no material changes in the status of its activities. - FY2018-Q1RestatedAnnual report
「R&D expenditures for the Group as a whole during the first quarter of the current consolidated cumulative period were ¥1,666 million. There were no material changes in the status of the Group’s R&D activities during the first quarter of the current consolidated cumulative period.」
The company stated that R&D expenditures were ¥1,666 million and that there had been no material changes in the status of its activities. - FY2017AdvancedAnnual report
「In new product development, the company used industry-academia-government collaboration in Japan and overseas to accelerate and improve the efficiency of R&D and worked to accelerate the launch of new products.」
The company used industry-academia-government collaboration to accelerate and improve the efficiency of R&D and worked to accelerate new product launches. R&D expenses were ¥6,635 million. - FY2017-Q3RestatedAnnual report
「R&D expenditures for the Group as a whole during the third quarter of the current consolidated cumulative period were ¥4,890 million. There were no material changes in the status of the Group’s R&D activities during the third quarter of the current consolidated cumulative period.」
The company stated that R&D expenditures were ¥4,890 million and that there had been no material changes in the status of its activities. - FY2017-Q2AdvancedAnnual report
「In new product development, the company strengthened industry-academia-government collaboration in Japan and overseas and worked to accelerate R&D.」
The company strengthened industry-academia-government collaboration in Japan and overseas and worked to accelerate R&D. R&D expenditures during the second quarter of the current consolidated cumulative period were ¥3,219 million. - FY2017-Q1RestatedAnnual report
「To forge a new growth trajectory, the Group is pursuing the basic policies of the three-year 2016 Medium-Term Management Plan, which ends in fiscal 2016: accelerating the development of new products and businesses, expanding overseas operations, further strengthening its management foundation, and reorganizing into a strategic organization. At the same time, it is working to develop new markets and expand sales of high-performance, high-value-added products, reduce production costs, and build on its management efforts toward sustainable growth. R&D expenditures for the Group as a whole during the first quarter of the current consolidated cumulative period were ¥1,631 million.」
The company reiterated accelerating the development of new products and businesses as a basic policy. It stated that R&D expenditures were ¥1,631 million and that there had been no material changes. - FY2016First statedAnnual report
「In particular, to accelerate the development of new products and businesses, the Group will further promote industry-government-academia collaboration in Japan and overseas and the overseas dispatch of young R&D personnel, expand its research themes, and work to improve the efficiency of new product development.」
The company cites industry-government-academia collaboration, overseas assignments for young R&D personnel, and the expansion of research themes as measures.